Mirati Therapeutics Stock Forecast, Price & News

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

Is Mirati Therapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mirati Therapeutics stock.
View analyst ratings for Mirati Therapeutics or view top-rated stocks.

How has Mirati Therapeutics' stock been impacted by Coronavirus?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRTX stock has increased by 75.8% and is now trading at $136.00.
View which stocks have been most impacted by COVID-19.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Mirati Therapeutics.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($1.55) earnings per share for the quarter, beating analysts' consensus estimates of ($2.87) by $1.32. The biotechnology company had revenue of $71.79 million for the quarter, compared to the consensus estimate of $1.41 million. The firm's revenue for the quarter was up 528.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.96) EPS.
View Mirati Therapeutics' earnings history.

What price target have analysts set for MRTX?

12 analysts have issued twelve-month price objectives for Mirati Therapeutics' shares. Their forecasts range from $173.00 to $285.00. On average, they anticipate Mirati Therapeutics' share price to reach $211.40 in the next twelve months. This suggests a possible upside of 55.4% from the stock's current price.
View analysts' price targets for Mirati Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:

• David D. Meek, Chief Executive Officer & Director
• Charles M. Baum, President, Director & Head-Research & Development (LinkedIn Profile)
• Daniel R. Faga, Executive VP, Chief Operating & Financial Officer
• James G. Christensen, Chief Scientific Officer & Executive VP (LinkedIn Profile)
• Philip Roberts, Senior Vice President-Technical Operations

Who are some of Mirati Therapeutics' key competitors?

Some companies that are related to Mirati Therapeutics include Genmab A/S (GNMSF), Genmab A/S (GMAB), Royalty Pharma (RPRX), Shiseido (SSDOY), Horizon Therapeutics Public (HZNP), Catalent (CTLT), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Takeda Pharmaceutical (TKPYY), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Elanco Animal Health (ELAN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF) and Dr. Reddy's Laboratories (RDY).
View all of MRTX's competitors.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (6.64%), BlackRock Inc. (5.15%), RTW Investments LP (2.88%), Franklin Resources Inc. (2.47%), Artal Group S.A. (2.32%) and Janus Henderson Group PLC (1.93%). Company insiders that own Mirati Therapeutics stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Jamie Christensen, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends for Mirati Therapeutics.

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, BlackRock Inc., Janus Henderson Group PLC, Clough Capital Partners L P, Morgan Stanley, Cubist Systematic Strategies LLC, Integral Health Asset Management LLC, and Two Sigma Advisers LP. Company insiders that have sold Mirati Therapeutics company stock in the last year include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Jamie Christensen, Ltd Braslyn, Maria E Martinez, and Vickie S Reed.
View insider buying and selling activity for Mirati Therapeutics or view top insider-selling stocks.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Artal Group S.A., Wellington Management Group LLP, Eagle Asset Management Inc., Lord Abbett & CO. LLC, Caption Management LLC, Jennison Associates LLC, and International Biotechnology Trust PLC.
View insider buying and selling activity for Mirati Therapeutics or or view top insider-buying stocks.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $136.00.

How much money does Mirati Therapeutics make?

Mirati Therapeutics has a market capitalization of $7.05 billion and generates $13.40 million in revenue each year. The biotechnology company earns $-357.94 million in net income (profit) each year or ($9.53) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

Mirati Therapeutics employs 200 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

Where are Mirati Therapeutics' headquarters?

Mirati Therapeutics is headquartered at 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 332-3410 or via email at [email protected].